Bajaj Healthcare launches Corona drug, Favijaj will get Favipiravir’s generic tablet

Bajaj Healthcare has launched a new drug for use in the treatment of Kovid-19.

Bajaj Healthcare has launched a new drug for use in the treatment of Kovid-19.

According to Bajaj Healthcare, the Drug Controller General of India (DCGI) has approved him to manufacture and sell generic Favipiravir under the name of Favizaj. This drug is effective in mild and moderate cases of Kovid-19.

New Delhi. Every day among the patients of the growing corona infection in the country, everyone is working to help in dealing with this problem in their own way. In this series, Indian pharmaceutical manufacturer Bajaj Healthcare Limited (Bajaj Healthcare) has announced success in making the drug of Corona virus. Bajaj Healthcare has said that it has launched a generic version of Favipiravir, an anti-viral drug used to treat patients with corona infection. This drug of the company will be available in the form of tablet in the name of Favijaj. This drug is considered effective in treating mild and moderate cases of Kovid-19. DCGI allowed manufacture and marketing of favijas Bajaj Bajaj Healthcare informed Bombay Stock Exchange (BSE) that the drug regulator Drug Controller General of India (DCGI) has allowed it to produce and market favijas in the country. Anil Jain, Joint Managing Director (Joint MD) of the company said that the availability of favijas will help to overcome the shortage of Corona medicines in the country. Also, patients will get an effective option for treatment, which will reduce their difficulties. Let me tell you that at present, Remedisvir is considered to be the most effective drug in the treatment of corona patients, due to which it has decreased. In such a situation, this medicine can prove to be very helpful. read this also- Indian Railways canceled 16 more trains in Bihar, Bengal, Jharkhand, check out the complete list before leaving homeBajaj Healthcare credited the research team for the preparation of the formula Bajaj Healthcare says that it has formulated Favipiravir formulation for this tablet and its active pharmaceutical ingredient (API) through its own research. The credit goes to the company’s own Research and Development (R&D) team. Bajaj Healthcare shares closed at Rs 583.05, up 10.85 per cent on the BSE today.

Leave a Reply

Your email address will not be published. Required fields are marked *